Last reviewed · How we verify
Klacid
At a glance
| Generic name | Klacid |
|---|---|
| Also known as | clarithromycin |
| Sponsor | Zahra Vahdat Shariatpanahi |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR
- 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication (PHASE3)
- Vonoprazan for Helicobacter Pylori Eradication in Adolescents (PHASE3)
- The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) (PHASE1)
- Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication (PHASE4)
- Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma (PHASE2)
- Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication (PHASE4)
- Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Klacid CI brief — competitive landscape report
- Klacid updates RSS · CI watch RSS
- Zahra Vahdat Shariatpanahi portfolio CI